<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088919</url>
  </required_header>
  <id_info>
    <org_study_id>1941-CL-0060</org_study_id>
    <nct_id>NCT01088919</nct_id>
  </id_info>
  <brief_title>A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open Label, Randomized, Crossover, Drug Interaction Study of the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride After Separate and Concomitant Administration to Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pharmacokinetics, pharmacodynamics and safety&#xD;
      following the administration of ASP1941 and pioglitazone hydrochloride in multiple and single&#xD;
      doses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will be enrolled at one center and confined to the unit for up to 23 days.&#xD;
      Subjects will be dosed in the fasting state in one of the four groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic variables assessment through analysis of blood samples</measure>
    <time_frame>Day 1 and up to Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic variables assessment through analysis of blood and urine samples</measure>
    <time_frame>Day -1 and up to Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by recording of adverse events, laboratory assessments, electrocardiograms (ECGs), vital signs and physical examinations</measure>
    <time_frame>Day 1 through scheduled group check out (Day 13 and up to Day 21) or early termination</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <condition>Pharmacokinetics of ASP1941</condition>
  <arm_group>
    <arm_group_label>Dosing Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Regimen 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1941</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Dosing Regimen 1</arm_group_label>
    <arm_group_label>Dosing Regimen 2</arm_group_label>
    <arm_group_label>Dosing Regimen 3</arm_group_label>
    <arm_group_label>Dosing Regimen 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone hydrochloride</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Dosing Regimen 1</arm_group_label>
    <arm_group_label>Dosing Regimen 2</arm_group_label>
    <arm_group_label>Dosing Regimen 3</arm_group_label>
    <arm_group_label>Dosing Regimen 4</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject weighs at least 50 kg, and has a body mass index (BMI) of 18 to 32 kg/m2&#xD;
             inclusive&#xD;
&#xD;
          -  The subject's 12-lead electrocardiogram (ECG) results are normal&#xD;
&#xD;
          -  The female subject must be at least two years postmenopausal, surgically sterile or&#xD;
             practicing effective birth control and not pregnant or lactating&#xD;
&#xD;
          -  The male or female subject agrees to practice highly effective birth control from&#xD;
             Screening until 7 days post last dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has a history or evidence of any clinically significant (as determined by&#xD;
             the investigator) cardiovascular, endocrinologic, hematologic, hepatic, immunologic,&#xD;
             metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or&#xD;
             other major disease or malignancy (excluding non-melanoma skin cancer)&#xD;
&#xD;
          -  The subject has any condition possibly affecting drug absorption (e.g., gastrectomy)&#xD;
&#xD;
          -  The subject has history of consuming more than 14 units of alcoholic beverages per&#xD;
             week within 6 months prior to screening or has a history of alcoholism or&#xD;
             drug/chemical/substance abuse within past 2 years prior to screening or the subject&#xD;
             tests positive for alcohol or drugs of abuse&#xD;
&#xD;
          -  The subject has/had febrile illness or symptomatic, viral, bacterial (including upper&#xD;
             respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to&#xD;
             clinic check in&#xD;
&#xD;
          -  The subject has a supine mean systolic blood pressure &lt; 90 or &gt; 160 mmHg and a mean&#xD;
             diastolic blood pressure &lt; 50 or &gt; 90 mmHg, or pulse rate higher than 100 beats per&#xD;
             min (bpm)&#xD;
&#xD;
          -  The subject has a 12-lead ECG demonstrating QTc &gt;470 msec (female) or &gt;450 msec (male)&#xD;
&#xD;
          -  The subject is known positive for human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
          -  The subject has a positive test for tuberculosis (TB), hepatitis C antibody, or&#xD;
             positive for hepatitis B antigen (HBsAg)&#xD;
&#xD;
          -  The subject has used prescription or non-prescription drugs within 2 weeks or 5&#xD;
             half-lives (whichever is longer) or complementary and alternative medicines (CAM)&#xD;
             within 14 days prior to study drug administration (excluding oral contraceptives,&#xD;
             hormone replacement therapy [HRT], and acetaminophen)&#xD;
&#xD;
          -  The subject has had any significant blood loss, donated one unit (450 mL) of blood or&#xD;
             more, or received a transfusion of any blood or blood products within 60 days or&#xD;
             donated plasma within 7 days prior to clinic admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>April 15, 2010</last_update_submitted>
  <last_update_submitted_qc>April 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sr Manager Clinical Trials Registry</name_title>
    <organization>Astellas Pharma Global Development</organization>
  </responsible_party>
  <keyword>ASP1941</keyword>
  <keyword>Actos</keyword>
  <keyword>pioglitazone hydrochloride</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Ipragliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

